Dexamethasone and Sitagliptin

Phase 1Small molecule

Dexamethasone and Sitagliptin is one of 53 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukemiaEnrolling by invitation

Acute Myeloid LeukemiaPhase 1

Enrolling by invitation

Competition

Competitive Landscape

235 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Phase 3

60 2

Xospata

Astellas

Phase 3

24 3

Vepesid

AAvyxa

Phase 3

52 4

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

38 5

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

32 6

Neupogen

EEastern Cooperative Oncology Group

Phase 3

30 7

Nexavar

Bayer

Phase 3

12 8

Busulfex

Akero Therapeutics

Phase 3

27 9

Cytoxan

BBaxter Healthcare Corporation

Novantrone

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glucocorticoid1 trial

Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy

Completed·UUniversity of Vermont·N/A·NCT01488279·10 enrolled

Acute Myeloid Leukemia1 trial

A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML

Enrolling by invitation·UUniversity of Vermont·Phase 1·NCT07014462·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Dexamethasone and Sitagliptin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dexamethasone and Sitagliptin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dexamethasone and Sitagliptin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Vermont company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Vermont

Dexamethasone and Sitagliptin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Glucocorticoid1 trial

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News